A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes
Nephrology Dialysis Transplantation · 2023
DOI: 10.1093/ndt/gfac305 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von Jennifer S Lees und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Sciences, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Hypertension. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chief Scientist Office, British Heart Foundation.
Abstract (Originalsprache)
Background
Vascular endothelial growth factor inhibitors (VEGFis) have transformed the treatment of many retinal diseases, including diabetic maculopathy. Increasing evidence supports systemic absorption of intravitreal VEGFi and development of significant cardiorenal side effects.
Methods
We conducted a systematic review and meta-analysis (PROSPERO: CRD42020189037) of randomised controlled trials of intravitreal VEGFi treatments (bevacizumab, ranibizumab and aflibercept) for any eye disease. Outcomes of interest were cardiorenal side effects (hypertension, proteinuria, kidney function decline and heart failure). Fixed effects meta-analyses were conducted where possible.
Results
There were 78 trials (81 comparisons; 13 175 participants) that met the criteria for inclusion: 47% were trials in diabetic eye disease. Hypertension (29 trials; 8570 participants) was equally common in VEGFi and control groups {7.3 versus 5.4%; relative risk [RR] 1.08 [95% confidence interval (CI) 0.91–1.28]}. New or worsening heart failure (10 trials; 3384 participants) had a similar incidence in VEGFi and control groups [RR 1.03 (95% CI 0.70–1.51)]. Proteinuria (5 trials; 1902 participants) was detectable in some VEGFi-treated participants (0.2%) but not controls [0.0%; RR 4.43 (95% CI 0.49–40.0)]. Kidney function decline (9 trials; 3471 participants) was similar in VEGFi and control groups. In participants with diabetic eye disease, the risk of all-cause mortality was higher in VEGFi-treated participants [RR 1.62 (95% CI 1.04–2.46)].
Conclusion
In trials of intravitreal VEGFi, we did not identify an increased risk of cardiorenal outcomes, although these outcomes were reported in only a minority of cases. There was an increased risk of death in VEGFi-treated participants with diabetic eye disease. Additional scrutiny of post-licensing observational data may improve the recognition of safety concerns in VEGFi-treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Sciences, University of Glasgow, Glasgow, UK.
- Glasgow Centre for Ophthalmic Research, NHS Greater Glasgow and Clyde, Glasgow, UK.
- Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
ORCID-Profile: Jennifer S Lees, Laurie P Tomlinson, Patrick B Mark
Förderung
- Chief Scientist Office
- British Heart Foundation
Zitieren
APA
Lees, J. S., Dobbin, S. J. H., Elyan, B. M. P., Gilmour, D. F., Tomlinson, L. P., Lang, N. N., & Mark, P. B. (2023). A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac305
Vancouver
Lees JS, Dobbin SJH, Elyan BMP, Gilmour DF, Tomlinson LP, Lang NN, et al. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfac305
BibTeX
@article{Lees2023,
author = {Lees, Jennifer S and Dobbin, Stephen J H and Elyan, Benjamin M P and Gilmour, David F and Tomlinson, Laurie P and Lang, Ninian N and Mark, Patrick B},
title = {A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
doi = {10.1093/ndt/gfac305}
}
EUVIMED